Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are 55 years of age or older at the time of signing the consent form
• You have geographic atrophy (GA) in both eyes caused by age-related macular degeneration (AMD), confirmed by specialist imaging, and at least one eye has a GA area within a specific size range (confirm with trial site)
• Your vision in both eyes is at least good enough to navigate your surroundings (roughly 20/400 or better)
• Your vision score falls within a certain range when tested using a standard eye chart called an ETDRS chart (confirm with trial site for exact values)
• The sensitivity of your central vision, measured by a specific eye test called microperimetry, meets a minimum level (confirm with trial site)
• You are willing and able to sign a consent form and take part in all study visits and assessments

Who may not be able to join:

• Your macular atrophy (damage to the central part of the retina) is caused by something other than AMD
• You have any other condition affecting the central part of your eye, beyond what is expected with AMD
• You have had or currently have the "wet" form of AMD (also called choroidal neovascularization) in either eye
• Your retinal disease is caused by an inherited condition, short-sightedness, or a condition called Stargardt disease
• You have previously had a surgical procedure inside your eye called a vitrectomy
• You have had any previous treatment for AMD or any injection into the eye for any reason (vitamin/mineral supplements such as AREDS formula are allowed)
• You have had eye surgery (other than cataract surgery more than 6 months ago) or laser treatment to the eye within 3 months of screening, or you may need eye surgery during the study
• You have ever had laser treatment, surgery on the macula, or retinal surgery in the eye being studied
• You have had an eye or surrounding area infection within the past 12 weeks
• You have a history of eye inflammation (uveitis) or a serious eye infection (endophthalmitis) in either eye
• You have signs of diabetic eye disease in either eye, or your blood sugar control has been poor in the past 12 months (confirm with trial site)
• You have a high degree of short-sightedness or long-sightedness (6 diopters or more) in the eye being studied
• You have uncontrolled eye pressure (glaucoma-related issues), even while using eye pressure–lowering drops, or have glaucoma damage to the eye (confirm with trial site)
• You have another retinal condition or eye disorder that could raise safety concerns, as judged by the study doctor
• You have a condition affecting the clarity of your eye (such as a significant cataract or corneal problem) that could interfere with eye examinations or imaging during the study
• You do not have a natural or artificial lens properly in place in the study eye (confirm with trial site)
• You have a medical or mental health condition that, in the study doctor's opinion, makes it unlikely you could attend regular follow-up visits, or that puts you at general health risk
• You have taken part in another clinical trial or used an experimental treatment within the past 6 months (or longer, depending on the treatment)
• You have had abnormal blood or other lab test results that the study doctor considers significant and unsuitable for participation
• You are known to be allergic or sensitive to any medications used during the study
• The study doctor believes the risks of joining outweigh any possible benefits for you
• You have ever received gene therapy or cell therapy of any kind (eye-related or otherwise)
• You have taken certain medications that can affect the retina or optic nerve, including (but not limited to) chloroquine (for more than 30 days total in your lifetime), hydroxychloroquine, tamoxifen, ethambutol, or certain other listed drugs (confirm full list with trial site)

Important: Always verify eligibility with the trial site directly before applying.